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Abstract
Introduction: The objective of this study is to develop evidence-based guidelines that recommend effective, safe and cost-
effective thromboprophylaxis strategies in patients with spinal cord injury (SCI).
Methods: A systematic review of the literature was conducted to address key questions relating to thromboprophylaxis in SCI.
Based on GRADE (Grading of Recommendation, Assessment, Development and Evaluation), a strong recommendation is worded
as “we recommend,” whereas a weaker recommendation is indicated by “we suggest.”
Results: Based on conclusions from the systematic review and expert panel opinion, the following recommendations were
developed: (1) “We suggest that anticoagulant thromboprophylaxis be offered routinely to reduce the risk of thromboembolic
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events in the acute period after SCI;” (2) “We suggest that anticoagulant thromboprophylaxis, consisting of either subcutaneous
low-molecular-weight heparin or fixed, low-dose unfractionated heparin (UFH) be offered to reduce the risk of thromboembolic
events in the acute period after SCI. Given the potential for increased bleeding events with the use of adjusted-dose UFH, we
suggest against this option;” (3) “We suggest commencing anticoagulant thromboprophylaxis within the first 72 hours after injury,
if possible, in order to minimize the risk of venous thromboembolic complications during the period of acute hospitalization.”
Conclusions: These guidelines should be implemented into clinical practice in patients with SCI to promote standardization of
care, decrease heterogeneity of management strategies and encourage clinicians to make evidence-informed decisions.
Keywords
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Summary of Recommendations
We suggest that anticoagulant thromboprophylaxis be
offered routinely to reduce the risk of thromboembolic
events in the acute period after spinal cord injury.
Quality of Evidence: Low
Strength of Recommendation: Weak
We suggest that anticoagulant thromboprophylaxis, consist-
ing of either subcutaneous low-molecular-weight heparin
or fixed, low-dose unfractionated heparin, be offered to
reduce the risk of thromboembolic events in the acute
period after spinal cord injury. Given the potential for
increased bleeding events with the use of adjusted-dose
unfractionated heparin, we suggest against this treatment
option.
Quality of Evidence: Low
Strength of Recommendation: Weak
We suggest commencing anticoagulant thromboprophylaxis
within the first 72 hours after injury, if possible, in order
to minimize the risk of venous thromboembolic compli-
cations during the period of acute hospitalization.
Quality of Evidence: Low
Strength of Recommendation: Weak
Introduction
Patients with spinal cord injury (SCI) are at an increased risk of
venous thromboembolism (VTE) due to hypercoagulability,
venous stasis, and venous endothelial injury.1 Interruption of
neurologic impulses and paralysis cause physical and meta-
bolic changes in the leg veins leading to decreased distensibil-
ity, increased flow resistance, and vessel injury.2 Furthermore,
immobilization of the lower extremities results in venous stasis
and often leads to the formation of venous thrombi. VTE,
which includes both deep vein thrombosis (DVT) and pulmon-
ary embolism (PE), is a significant cause of morbidity and
mortality in SCI patients. Venous thrombi most commonly
form in the lower extremities; here they may either undergo
endogenous fibrinolysis and recanalization or they may propa-
gate and embolize to the pulmonary system.1 Obstruction of the
pulmonary arteries may lead to a number of life-threatening
physiologic changes, including impaired gas exchange,
cardiovascular compromise and right-sided heart failure. The
prevention of DVT and PE is essential in this high-risk popu-
lation. Prophylactic treatment with anticoagulants and mechan-
ical strategies may significantly reduce the risk of VTE events
in these patients. However, there are concerns that use of antic-
oagulant thromboprophylaxis may increase the risk of bleeding
complications and possibly worsen neurologic deficits.3,4
This guideline provides evidence-based recommendations on
thromboprophylaxis strategies in patients with acute SCI. The
systematic review aimed to determine (1) the most effective
anticoagulant and/or mechanical methods to prevent VTE and
(2) the optimal timing of administering thromboprophylaxis.
The ultimate goal of this guideline is to improve outcomes and
reduce morbidity in patients with SCI by promoting standardiza-
tion of care, encouraging clinicians to make more evidence-
informed decisions and influencing policy changes to ensure
adoption of recommended treatments. An introductory article
in this focus issue, titled “A Clinical Practice Guideline for the
Management of Acute Spinal Cord Injury: Introduction, Ratio-
nale and Scope,” provides further background information on
SCI and summarizes the rationale, scope, and specific aspects of
care covered by this guideline.
These guidelines are intended to be used by emergency
room physicians, critical care specialists, anesthesiologists,
vascular medicine physicians, neurosurgeons, neurologists,
spine surgeons, and hospitalists.
Methods
This guideline was developed under the auspices of AOSpine
North America, AOSpine International and the American
Association and Congress of Neurological Surgeons. A multi-
disciplinary guideline development group (GDG) was formed
and consisted of clinicians from a broad range of specialties as
well as patient representation. The GDG was solely responsible
for guideline development and was editorially independent
from all funding sources. Members were required to disclose
financial and intellectual conflicts of interest (Appendix, Chap-
ter 2). A guideline development protocol, based on the Confer-
ence on Guideline Standardization (COGS) checklist,5,6 was
created to outline the rationale and scope of the guideline and
to direct its development. Systematic reviews were conducted
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based on accepted methodological standards to summarize the
evidence informing the recommendations. Details of specific
methods used for each topic are outlined in the individual
reviews included in this focus issue. Methods outlined by the
Grading of Recommendation, Assessment, Development and
Evaluation (GRADE) Working Group were used to assess the
overall quality (strength) of evidence for critical outcomes.7,8
The GRADE Guideline Development Tool was used to docu-
ment the guideline development process, rank the importance
of outcomes, weigh the benefits and harms of various options,
and determine the strength of recommendations.9-12 Methodol-
ogists with no financial or intellectual conflicts of interest
worked closely with clinical authors to conduct the systematic
reviews and provided methodological expertise on the guide-
line development process. Guideline development methods are
provided in another article included in this focus issue:
“Guidelines for the Management of Degenerative Cervical
Myelopathy and Acute Spinal Cord Injury: Development Pro-
cess and Methodology.”
Part 1. The Use of Anticoagulant
Thromboprophylaxis Strategies
Population Description: Patients with acute SCI
Key Question: Should anticoagulant thromboprophylaxis be
employed to reduce the risk of thromboembolic events in
the acute period after SCI?
Recommendation 1: We suggest that anticoagulant throm-
boprophylaxis be offered routinely to reduce the risk of
thromboembolic events in the acute period after spinal
cord injury.
Quality of Evidence: Low
Strength of Recommendation: Weak
Evidence Summary
A systematic review of the literature was conducted to deter-
mine the efficacy, safety, and timing of anticoagulant throm-
boprophylaxis in patients with acute SCI. One of the main
objectives of this review was to evaluate the effectiveness and
safety of anticoagulant thromboprophylaxis compared to no
prophylaxis or to placebo.
Three randomized controlled trials met inclusion criteria
and compared the risk of DVT in patients treated with low-
molecular-weight heparin (LMWH) or unfractionated heparin
(UFH) to those receiving no prophylaxis or placebo.13-15 Based
on low level evidence, patients treated with enoxaparin have a
lower rate of DVT (5.4%) than those who received no
anticoagulant thromboprophylaxis (21.6%) (risk difference
[RD] ¼ 16.2, 95% CI ¼ 1.1 to 31.4; risk ratio [RR] ¼ 4.0,
95% CI ¼ 0.91 to 17.6; P ¼ .09). Furthermore, rates of DVT
did not significantly differ between the UFH and the placebo/
no prophylaxis group (1.8% and 3%, respectively in one trial14
and 50% and 47%, respectively, in another trial15). Risk of
bleeding, mortality or PE were not reported in any of these 3
trials.
Rationale for Recommendation
The outcomes most critical for decision-making were reduced
risk of DVT and PE without increased risk of bleeding and
mortality. The overall certainty of the evidence was unani-
mously rated as low as (1) rates of bleeding, mortality and
PE were not compared between various pharmacological stra-
tegies and placebo/no prophylaxis and (2) the conclusions sur-
rounding rates of DVT were derived from studies with a serious
risk of bias, imprecision, and unknown consistency.
The GDG unanimously agreed that there was no important
uncertainty or variability about how much stakeholders value
the main outcomes. The group believed that clinicians, patients
and payers would similarly value a reduced risk of thromboem-
bolic events due to decreased risk of mortality and morbidity
and lower associated costs.
The anticipated desirable effects vary based on which type
of anticoagulant strategy is studied (agreement among mem-
bers of the GDG). Patients who received enoxaparin had a
reduced risk of DVT (5.4%) compared to patients who did not
receive prophylaxis (21.6%); however, this association did not
reach significance using the Fisher exact test. In contrast, there
was no difference in risk of DVT in patients treated with UFH
versus placebo or no treatment. The GDG discussed that clin-
ical judgment is more important than current evidence to deter-
mine whether the anticipated desirable effects are large; despite
nonsignificant findings, anticoagulant thromboprophylaxis
should be prescribed routinely to reduce the risk of VTE.
The anticipated undesirable effects, specifically treatment-
associated bleeding, are uncertain (agreement among members
of the GDG). There were no studies that carefully evaluated the
difference in risk of adverse events between the treatment and
no prophylaxis groups. The GDG unanimously agreed that the
relative size of the desirable and undesirable effects also varies
based on the type of anticoagulant thromboprophylaxis. For
enoxaparin, the anticipated desirable effects are probably large
relative to the anticipated undesirable effects as it reduces the
risk of DVT without any known safety issues.13
In the absence of evidence, the GDG used their clinical
expertise to discuss the resources required for anticoagulant
thromboprophylaxis. The GDG unanimously agreed that the
resources are likely small since these strategies (LMWH or
UFH) are relatively simple and inexpensive; this is especially
true when considering cost savings associated with reduction in
VTE as well as total resources required to manage patients with
SCI. Unfortunately, there are no reports on the cost-
effectiveness of anticoagulant thromboprophylaxis versus no
treatment and so the cost benefit ratio of this option is uncertain
(agreement among members of the GDG).
All members of the GDG believed that a recommendation
for anticoagulant thromboprophylaxis in patients with SCI
would probably reduce health inequities since these treatments
are widely available and relatively inexpensive. Furthermore,
this option is probably acceptable to key stakeholders and fea-
sible to implement because of its potential benefits in reducing
the risk of VTE and because there are no foreseeable barriers.
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Considering all these factors, all members of the GDG voted
that the desirable consequences probably outweigh the undesir-
able consequences in most settings; this led to the formation of a
weak recommendation for anticoagulant thromboprophylaxis in
patients with SCI to reduce the risk of thromboembolic events.
Part 2. Types of Anticoagulant
Thromboprophylaxis Strategies
Population Description: Patients with acute SCI
Key Questions:
What anticoagulant thromboprophylaxis should be
employed to reduce the risk of thromboembolic events
in the acute period after traumatic SCI?
Should enoxaparin versus dalteparin be used to reduce the
risk of thromboembolic events in the acute period after
traumatic SCI?
Should fixed, low-dose versus adjusted-dose UFH be used
to reduce the risk of thromboembolic events in the acute
period after traumatic SCI?
Should LMWH versus UFH be used to reduce the risk of
thromboembolic events in the acute period after trau-
matic SCI?
Recommendation 2: We suggest that anticoagulant throm-
boprophylaxis, consisting of either subcutaneous LMWH
or fixed, low-dose UFH, should be offered to reduce the
risk of thromboembolic events in the acute period after
spinal cord injury. Given the potential for increased
bleeding events with the use of adjusted-dose unfractio-
nated heparin, we suggest against this treatment option.
Quality of Evidence: Low
Strength of Recommendation: Weak
Evidence Summary
The systematic review also aimed to compare the efficacy and
safety of various anticoagulant strategies: (1) LMWH(enoxaparin)
versus LMWH (dalteparin); (2) fixed, low-dose versus adjusted-
doseUFH; and (3)LMWH(tinzaparin anddalteparin) versusUFH.
Based on low-quality evidence, there is little to no difference
in the rate of DVT (RD ¼ 1.6, 95% CI ¼ 7.3 to 10.5; RR ¼
1.35, 95% CI¼ 0.24 to 7.72; P ¼ 1.0), PE (no events), bleeding
(RD¼ 2.4, 95% CI¼9.6 to 4.7; RR¼ 0.45, 95% CI¼ 0.04 to
4.8; P ¼ .6) and mortality (no events in either group) between
patients treated with enoxaparin versus dalteparin.16 There is
low-quality evidence that the risk of DVT is 3 times higher in
patients who receive fixed, low-dose UFH compared to
adjusted-dose heparin (RD ¼ 13.8, 95%CI ¼ 3.6 to 31.2;
RR ¼ 3.0, 95%CI ¼ 0.66 to 13.7; P ¼ .25).17 The rate of
bleeding, however, is significantly higher in patients treated with
adjusted-dose heparin (24.1%) than in those receiving low-dose
(0%) (RD ¼ 24.1, 95% CI ¼ 8.6 to 39.7; P ¼ .01).18,19
Rationale for Recommendation
In order to advise what anticoagulant thromboprophylaxis
should be used to minimize the risk of VTE, we compared the
efficacy and safety of enoxaparin versus dalteparin, fixed, low-
dose versus adjusted-dose UFH and LMWH (tinzaparin or dal-
teparin) versus UFH. For all comparisons, the outcomes most
critical for decision-making were reduced risk of DVT and PE
without increased risk of bleeding and mortality.
A single study by Chiou-Tan et al16 evaluated the efficacy
and safety of enoxaparin versus dalteparin. The strength of evi-
dence was low due to serious risk of bias and imprecision (wide
confidence intervals or small sample size/low event rates). A
single study by Green et al20 compared the risk of DVT, PE,
and mortality between patients treated with fixed, low-dose ver-
sus adjusted-dose UFH. The strength of evidence was also low
due to risk of bias and imprecision (wide confidence intervals or
small sample size/low event rates). The strength of evidence was
upgraded from low to moderate for the finding that adjusted-
dose UFH significantly increased the risk of bleeding due to
large magnitude of effect (RR ¼ 24.1, 95% CI ¼ 8.6 to 39.7).
Two studies compared the efficacy and safety of UFH versus
LMWH (tinzaparin or dalteparin); all conclusions were graded
as low due to risk of bias and imprecision (wide confidence inter-
vals or small sample size/low event rates).18,19 The GDG unan-
imously agreed that the overall certainty of the evidencewas low.
The GDG felt that there was no important uncertainty or
variability about how much stakeholders would value the main
outcomes (agreement among members of the GDG). Clini-
cians, patients, and payers would similarly value a reduced risk
of thromboembolic events due to decreased risk of mortality
and morbidity and lower associated costs.
The anticipated desirable effects of anticoagulant thrombo-
prophylaxis are reduced risk of DVT, PE, and mortality. The
GDG unanimously agreed that the anticipated desirable effects
of one anticoagulant thromboprophylaxis strategy compared to
another are probably not large: (1) there was no difference in
the risk of DVT or PE between patients treated with enoxaparin
versus dalteparin or those receiving UFH versus LMWH (tin-
zaparin or dalteparin) and (2) the risk of DVT in a fixed, low-
dose UFH group was 3 times larger than in the adjusted-dose
group; however, the confidence interval of the relative risk was
wide and spanned one.
The potential undesirable effect of anticoagulant thrombo-
prophylaxis is bleeding. There was no difference in the risk of
bleeding or mortality in patients treated with enoxaparin versus
dalterparin or UFH versus LMWH (tinzaparin or dalteparin). In
contrast, patients receiving adjusted-dose heparin were at a
higher risk of bleeding events than patients treated with fixed,
low-dose heparin. Based on these findings, the GDG unani-
mously agreed that the undesirable effects of enoxaparin versus
dalteparin and UFH versus LMWH (tinzaparin or dalteparin)
are probably small. In contrast, the undesirable effects of
adjusted-dose versus fixed, low-dose UFH are probably not
small. As a result, the GDG agreed that the size of the antici-
pated undesirable effects vary based on treatment comparison.
In the absence of evidence, the GDG used their clinical exper-
tise to discuss the resources required for anticoagulant thrombo-
prophylaxis. The GDG unanimously agreed that the resources
are likely small since these strategies are relatively simple and
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inexpensive; this is especially true when considering cost sav-
ings associated with a reduction in VTE as well as total resources
required to manage patients with SCI. Unfortunately, there are
no reports on the relative cost-effectiveness of various anticoa-
gulant thromboprophylaxis and so the cost-benefit ratio of each
strategy is uncertain. The GDG unanimously agreed that the cost
of treatment is small but so are the differences in net benefits
when comparing various anticoagulant strategies. Since there is
limited data to suggest superior outcomes of one treatment over
another, direct drug and administration costs may have a large
impact on decision making. Future cost-effectiveness studies are
required to confirm this hypothesis and must consider costs asso-
ciatedwith drugacquisition and administration, aswell as costs of
managing VTE, increased length of stay, and adverse events.
The GDG believed that a recommendation for a specific
anticoagulant thromboprophylaxis strategy in patients with SCI
would probably reduce health inequities since these treatments
are widely available and relatively inexpensive (agreement
among members of the GDG). It is uncertain whether these
options are acceptable to key stakeholders: (1) the option of
adjusted-dose UFH is probably not acceptable to key stake-
holders given the increased risk of bleeding and (2) all other
comparisons did not indicate superior outcomes for one
approach. The GDG unanimously agreed that these options are
probably feasible to implement due to the risk-benefit profile
and because there are no foreseeable barriers.
The GDG believed that, for the comparisons of enoxaparin
versus dalteparin and LMWH versus UFH, the anticipated
desirable and undesirable effects were closely balanced or
uncertain (agreement among members of the GDG). This led
to the suggestion of either LMWH or fixed, low-dose UFH to
minimize the risk of thromboembolic events in the acute period
after SCI. When comparing adjusted-dose and fixed, low-dose
UFH, the GDG unanimously agreed that the undesirable con-
sequences associated with adjusted-dose UFH probably out-
weigh the desirable consequences in most settings. This
resulted in a suggestion against the use of adjusted-dose UFH.
Part 3. Timing of Initiation of Anticoagulant
Thromboprophylaxis Strategies
Population Description: Patients with acute SCI
Key Question: Should thromboprophylaxis be initiated
within 72 hours (vs after 72 hours) of SCI?
Recommendation 3:We suggest commencing anticoagulant
thromboprophylaxis within the first 72 hours after injury,
if possible, in order to minimize the risk of venous throm-
boembolic complications during the period of acute
hospitalization.
Quality of Evidence: Low
Strength of Recommendation: Weak
Evidence Summary
A third objective of the systematic review was to determine the
optimal timing to initiate and/or discontinue anticoagulant or
mechanical thromboprophylaxis and/or prophylactic inferior
vena cava filter following acute SCI. One prospective, non-
randomized observational study evaluated the risks of DVT and
PE in patients who received prophylaxis initiated within (early
group) versus after (late group) 72 hours of injury.21 Based on
low-quality evidence, the rate of DVT was significantly lower in
patients treated early (n¼ 2) compared with late (n¼ 46) (RD¼
24.1, 95% CI ¼ 17.1 to 31.2; RR ¼ 12.9, 95% CI ¼ 3.2 to 51.2;
P < .001). There was insufficient evidence to compare the rates
of PE between treatment groups.
Rationale for Recommendation
The outcomes most critical for decision-making were reduced
risk of DVT and PE without increased risk of bleeding and
mortality. The overall level of evidence for the timing of initia-
tion of anticoagulant thromboprophylaxis was rated as low for
DVT and insufficient for PE. The evidence for this recommen-
dation was derived from a single study by Aito et al that had no
serious risk of bias or indirectness.21 Consistency of these find-
ings, however, was unknown and the estimate of effect for risk
of DVT was imprecise. The level of evidence for risk of DVT
was upgraded for strength of association. The GDG unanimously
agreed that the overall certainty of the evidence was low.
The GDG unanimously agreed that there was no important
uncertainty or variability about how much stakeholders would
likely value the main outcomes. Clinicians, patients, and payers
would similarly value a reduced risk of thromboembolic events
due to decreased risk of mortality and morbidity and lower
associated costs.
The anticipated desirable effects are reduced risk of DVT,
PE, and mortality. The GDG unanimously agreed that the
anticipated desirable effects are probably large as early initia-
tion of thromboprophylaxis (72 hours), compared to late
initiation (>72 hours), is associated with a significantly reduced
risk of DVT. In contrast, the relative risk of PE could not be
calculated because no events occurred in either the early or late
treatment groups.
The anticipated undesirable effect of early prophylaxis is
treatment-associated bleeding. The GDG unanimously agreed
that it was uncertain whether the undesirable anticipated effects
were small as there were no studies that evaluated the differ-
ence in risk of adverse events between an early versus late
prophylaxis group. The GDG unanimously agreed that the
anticipated effects of early prophylaxis are probably large rela-
tive to the undesirable effects.
In the absence of evidence, the GDG used their clinical
expertise to discuss the resources required for early anticoagu-
lant thromboprophylaxis. The GDG unanimously agreed that
the resources are likely small since these strategies are rela-
tively simple and inexpensive; this is especially true when
considering cost savings associated with a reduction in VTE
as well as total resources required to manage patients with SCI.
Furthermore, there is likely no difference in the resource
requirement between early and late prophylaxis. The GDG
unanimously agreed that the benefits of early management
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(ie, reduced risk of DVT) probably outweigh the risk of bleed-
ing and the relatively small cost of this treatment; however,
further studies are required to evaluate the safety and cost-
effectiveness of early versus late prophylaxis.
The GDG believed that a recommendation for early initia-
tion of thromboprophylaxis in patients with SCI would proba-
bly reduce health inequities since these treatments are widely
available and relatively inexpensive (agreement among mem-
bers of the GDG). Furthermore, this option is probably accep-
table to key stakeholders and probably feasible to implement
due to its potential benefit in reducing the risk of DVT and
because there are no foreseeable barriers.
Considering all of these factors, the GDG voted that the
desirable consequences probably outweigh the undesirable
consequences in most settings (agreement among members of
the GDG); this led to the formation of a weak recommendation
for early initiation of prophylaxis in patients with SCI to mini-
mize the risk of venous thromboembolic complications during
the period of acute hospitalization.
Part 4. Combined Thromboprophylaxis
Strategies
Population Description: Patients with acute SCI
Key Question: Should mechanical or anticoagulant throm-
boprophylaxis be used in combination or alone?
The GDG agreed not to make a recommendation.
Evidence Summary
The systematic review aimed to determine the comparative
effectiveness and safety of mechanical and antithrombotic
agent prophylaxis used alone or in combination for preventing
DVT and PE after acute SCI. Three randomized controlled
trials compared the following treatments: (1) mechanical meth-
ods versus mechanical þ antiplatelet agents20 and (2) antic-
oagulant versus anticoagulant þ mechanical methods.15,22
Based on low-quality evidence, patients who receive a com-
bination of UFH and electric calf stimulation had a lower risk of
DVT than patients treated with UFH alone (RD ¼ 43.3, 95% CI
¼ 15.8 to 70.9; RR ¼ 7.5, 95% CI ¼ 1.06 to 53.03; P ¼ .02).15
There is also a reduced risk of DVT in patients treated with UFH
plus intermittent pneumatic compression (IPC) compared with
LMWH; however, this difference did not reach statistical sig-
nificance (RD¼ 15.4, 95% CI¼ 3.3 to 34.2; RR¼ 1.34, 95%
CI ¼ 0.92 to 1.95; P ¼ .12). Interestingly, patients treated with
LMWH alone have a lower risk of PE compared with patients
who receive UFH plus IPC (RD ¼ 13.2, 95% CI ¼ 0.9 to 25.4;
RR ¼ 0.28, 95% CI ¼ 0.08 to 0.98; P ¼ .06).22
Finally, based on low-quality evidence, a higher percentage
of patients experienced a DVT when treated with IPC alone
(40%) compared with IPC plus aspirin and dipyridamole
(25%)20; however, this difference was not statistically signifi-
cant (RD ¼ 15.0, 95% CI ¼ 19.9 to 49.9; RR ¼ 1.6, 95% CI
¼ 0.50 to 5.10; P ¼ .68).
Rationale for Recommendation
To address this question, we investigated the efficacy and
safety of antithrombotic or mechanical thromboprophylaxis
used alone or in combination. The outcomes most critical for
decision making were reduced risk of DVT and PE without
increased risk of bleeding and mortality. In the study by Green
et al,20 there was no difference in the risk of DVT or bleeding
between patients treated with IPC (mechanical alone) and those
receiving IPC plus aspirin and dipyridamole (mechanical þ
pharmacological). The strength of evidence for this finding was
low because of serious risk of bias and imprecision. Two stud-
ies compared outcomes between patients treated with anticoa-
gulant thromboprophylaxis alone versus those receiving a
combination of anticoagulant thromboprophylaxis and
mechanical treatments.15,22 A single study by Merli et al15
reported a higher risk of DVT in patients treated pharmacolo-
gically compared with patients receiving both pharmacological
and mechanical prophylaxis (RR ¼ 7.5; 95%CI ¼ 1.06 to
53.03; P ¼ .02). In the SCITI study, the risk of DVT was also
higher in the anticoagulant only (60.3%) group compared with
the combined anticoagulant and mechanical group (44.9%),
although this difference was not statistically significant.22 The
strength of evidence for these findings was low due to serious
risk of bias and imprecision. In the SCITI trial, there was a
tendency for patients treated with anticoagulant thrombopro-
phylaxis alone to have a lower rate of PE (5.2%) than those
treated with combined anticoagulant and mechanical prophy-
laxis (18.4%) (RR ¼ 0.28; 95% CI ¼ 0.08 to 0.98; P ¼ .06).22
The strength of evidence for this finding was low due to serious
risk of bias and imprecision. Interestingly, based on results
from the SCITI study, the outcomes most critical for decision
making (DVT and PE) were in opposite directions.22 This study
speculated that anticoagulant thromboprophylaxis may reduce
the progression of thrombi from distal to proximal veins,
whereas combined anticoagulant thromboprophylaxis and
mechanical treatments may protect against initial DVT forma-
tion. Once formed, however, compression devices may not
reduce the risk of clot propagation and PE formation. The risk
of major and minor bleeding and mortality did not differ
between treatment groups. Finally, there was no difference in
risk of major or minor bleeding or of mortality between patients
who received anticoagulant thromboprophylaxis alone versus
combined anticoagulant and mechanical thromboprophylaxis.
The strength of evidence for these findings was low due to
serious risk of bias and imprecision. The GDG unanimously
agreed that the overall certainty of evidence was low.
The GDG unanimously agreed that there was no important
uncertainty or variability about how much stakeholders would
value the main outcomes. The group believed that clinicians,
patients, and payers would similarly value a reduced risk of
thromboembolic events due to decreased risk of mortality and
morbidity and lower associated costs of diagnosis and treat-
ment of VTE.
The anticipated desirable effects are reduced risk of DVT,
PE, and mortality. The GDG unanimously agreed that the size of
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the anticipated desirable effects vary depending on the type of
prophylactic treatment and thromboembolic event: (1) patients
who receive UFH alone have a significantly higher risk of DVT
than those treated with a combination of UFH and electric calf
stimulation; the relative risk of this comparison was large and (2)
there was a tendency for patients treated with UFH and IPC to
have a higher risk of PE than patients treated with LMWH
prophylaxis alone; the effect size was large but the confidence
intervals were wide, indicating substantial variability.
The anticipated undesirable effect of combined treatment
strategies is bleeding. The GDG unanimously agreed that the
undesirable effects are probably small since there was no differ-
ence in risk of major or minor bleeding between patients who
received pharmacological or mechanical prophylaxis alone com-
pared with a combination of techniques. The GDG believed that
the relative size of anticipated desirable and undesirable effects
was uncertain given the variability of results across treatment
strategies (agreement among members of the GDG).
In the absence of evidence, the GDG used their clinical
expertise to discuss the resources required for combined antic-
oagulant and mechanical thromboprophylaxis. The GDG unan-
imously agreed that the resources are likely small since these
strategies are relatively simple and inexpensive; this is espe-
cially true when considering cost savings of diagnosis and
treatment of VTE as well as total resources required to manage
patients with SCI. The GDG believed that the balance between
costs and benefits depend on the type of prophylactic strategy
and thromboembolic event: (1) the net benefit of UFH and
electric calf stimulation is a reduction in the risk of DVT and
(2) the net benefit of LMWH alone (compared with UFH
and IPC) is to reduce the risk of PE; in these cases, the cost
of the treatment is probably small relative to the net benefit.
Unfortunately, there are no cost-effectiveness studies compar-
ing pharmacological or mechanical strategies alone to a com-
bined treatment approach.
The GDG believed that a recommendation for anticoagulant
and/or mechanical prophylaxis in patients with SCI would
probably reduce health inequities since these treatments are
widely available and relatively inexpensive (agreement among
members of the GDG). This option of combined versus not
combined prophylaxis is probably acceptable to key stake-
holders due to potential reduction in the risk of DVT and PE,
respectively. Furthermore, the risk of major or minor bleeding
does not differ between treatment groups. Finally, these options
are probably feasible to implement because of their potential
benefits in reducing the risk of VTE; however, there may be
barriers to routine mechanical prophylaxis with high
adherence.
The GDG believed that, for the comparisons of anticoagu-
lant or mechanical strategies alone versus combined treatment
approaches, the anticipated desirable and undesirable effects
were closely balanced or uncertain (agreement among mem-
bers of the GDG). Given the difference in direction for the risk
of DVT and PE, the GDG unanimously agreed that they were
unable to make a recommendation for or against combined
thromboprophylaxis. The GDG agreed that the appropriate
treatment strategy should be left to the discretion of the attend-
ing physician.
Evidence Gaps and Future Research
Recommendations
This guideline has identified important knowledge gaps in the
literature and areas of future research. These include (1) uncer-
tainty surrounding adverse effects as many studies did not
evaluate the difference in risk of bleeding between various
treatment groups; (2) limited evidence on the cost-
effectiveness of prophylactic strategies; and (3) a limited
understanding on the efficacy and safety of prophylactic IVC
insertion. Furthermore, the level of evidence for most of our
findings was low, suggesting that we have limited confidence
in the estimate of effect and that the true effect may be sub-
stantially different; further research is required to confirm these
conclusions.
Many of our findings were based on randomized controlled
trials; however, significant limitations exist in the current body
of evidence. These include (1) small sample sizes and low
event rates of DVT and PE make it challenging to compare the
efficacy and safety of various prophylactic strategies; (2) sig-
nificant clinical heterogeneity across studies prevent data pool-
ing and meta-analyses (eg, differences in populations,
pharmacological and mechanical treatment protocols, diagnos-
tic methods and outcomes); (3) relative risks and risk differ-
ences were often imprecise, likely due to low event numbers;
and (4) the majority of studies did not meet one or more criteria
of a good-quality randomized controlled trial, including ran-
dom sequence generation, statement of concealed allocation,
independent or blind assessment, adequate sample size, con-
trolling for possible confounding and complete follow-up.
Although these guidelines summarize the type and timing of
anticoagulation, there remain several knowledge gaps with
respect to VTE prophylaxis. These include the optimal dose and
duration of anticoagulant therapies, risks of bleeding following
certain treatments and predictors of VTE prophylaxis failures.
Future studies are required to fill these critical knowledge gaps.
The cost-effectiveness of DVT/PE prophylaxis in the trau-
matic SCI population is also largely unknown and should be
evaluated across medical systems worldwide. In doing so, it is
important to consider anticoagulant costs (including drug-
administration costs) as well as costs associated with length
of stay and adverse events. Since there is limited data to suggest
superior outcomes of one treatment over another, direct drug
and administration costs may have a large impact on decision-
making; future cost-effectiveness studies are required to con-
firm this hypothesis.
Beyond the scope of this guideline, other areas of interest
related to anticoagulation in SCI include (1) the risk factors and
natural history of VTE, (2) the incidence and prevalence of VTE
during the acute and rehabilitation phases of management as
well as in the postrehabilitation period, (3) the timing of resolu-
tion of DVT and PE risk following specific prophylactic strate-
gies, and (4) the value of screening for asymptomatic DVT.
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Implementation Considerations
It is expected that this guideline will influence clinical practice
and facilitate evidence-based decision-making. Dissemination
of the knowledge from this guideline is of critical importance
and will be accomplished at multiple levels:
 Presentation at international spine surgery, critical care,
neurosurgery, neurology, anesthesiology, and vascular
medicine conferences
 Scientific and educational courses in symposium format
 Webinar dissemination of information to a broad audi-
ence in an interactive format
 Publication of a focus issue in a peer-reviewed journal
 Submission to the National Guideline Clearinghouse
 AOSpine International Spinal Cord Injury Knowledge
Forum
There are no foreseeable barriers to the implementation of
these guidelines.
Internal Appraisal and External Review
of This Guideline
Vice-chairs of the GDG conducted an internal appraisal of the
final guideline using Appraisal of Guidelines for Research &
Evaluation II (AGREE II) standards.23 A multidisciplinary
group of stakeholders, including patients, were invited to
review the final draft prior to publication. Additional details
of these processes are found in the accompanying methods
article.
Plans for Updating
The guidelines will be reviewed by the primary sponsor and the
vice-chairs at 3 years to a maximum of 5 years following pub-
lication. The guideline will be updated when new evidence
suggests the need to modify our recommendations. An earlier
update will be considered if there are changes in (1) the evi-
dence related to harms and benefits, (2) outcomes that would be
considered important for decision-making, (3) ranking of cur-
rent critical and important outcomes, and (4) available inter-
ventions and resources.24
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